Effectiveness of very low doses of immunotherapy in advanced renal cell cancer

British Journal of Cancer

Volumn 76, Issue 4, 1997, Pages 541-544

  Buzio, C ^a,d   De Palma, G ^a   Passalacqua, R ^b   Potenzoni, D ^c   Ferrozzi, F ^a   Cattabiani, M A ^a   Manenti, L ^a   Borghetti, A ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY HOSPITAL OF PARMA   (Italy)

^c Azienda USL di Parma   (Italy)

^d Universitea degli Studi di Parma   (Italy)

Author keywords

Immunotherapy; Interferon alpha; Interleukin 2; Renal cell cancer

Indexed keywords

RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; FATIGUE; FEMALE; FEVER; HEART ARRHYTHMIA; HEARTBURN; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; KIDNEY CANCER; LIVER TOXICITY; MALAISE; MALE; MYALGIA; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VOMITING;

EID: 0030798858     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.422     Document Type: Article

References (18)

1. Atzpodien J, Korfer A, Franks CR, Poliwoda H and Kirchner H (1990) Home therapy with recombinant interleukin-2 and interteron-α2b in advanced human malignancies. Lancet 335: 1509-1512
2. Atzpodien J, Poliwoda H and Kirchner H (1991) Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol 18 (suppl. 7): 108-112
3. Bottiger LE (1970) Prognosis in renal carcinoma. Cancer 26: 780-787
4. Caligiuri MA (1993) Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications. Semin Oncol 20 (suppl. 9): 3-10
5. Caligiuri MA, Zmuidzinas A, Manley TJ, Levine H, Smith KA and Ritz J (1990) Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors. J Exp Med 171: 1509-1526
6. Fossa SD, Kramar A and Droz JP (1994) Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-α. Eur J Cancer 30A: 1310-1314
7. Lenardo MJ (1991) Interleukin-2 programs mouse αβ T lymphocytes for apoptosis. Nature 353: 858-861
8. Lissoni P, Barni S, Ardizzola A, Andres M, Scardino E, Carbellini P, Della Bitta R and Tancini G (1993) A randomized study of low-dose interleukin-2 subcutaneous immunotherapy versus interleukin-2 plus interferon-alpha as first line therapy for metastalic renal cell carcinoma. Tumori 79: 397-400
9. Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of cancer treatment. Cancer 47: 207-214
10. Palmer PA, Vinke J, Philip T, Negrier S, Atzpodien J, Kirchner H, Oskam R and Franks CR (1992) Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 3: 475-480
11. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG and White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin-2 alone. N Engl J Med 316: 889-897
12. Rosenberg SA, Yang JC, Topalian SL, Schwartzentruber DJ, Weber JS, Parkinson DR, Seipp CA, Einhorn JH and White DE (1994) Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271: 907-913
13. Schneekloth C, Korfer A, Hadam M, Hanninen EL, Menzel T, Schomburg A, Dallmann I, Kirchner H, Poliwoda H and Atzpodien J (1983) Low-dose interleukin-2 in combination with interferon-α effectively modulates biological response in vivo. Acta Haematol 89: 13-21
14. Sondel PM, Kohler PC, Hank JA, Moore KH, Rosenthal NS, Sosman JA, Bechhofer R and Storer B (1988) Clinical and immunological effects of recombinant interleukin 2 given by repetitive weekly cycles to patients with cancer. Cancer Res 48: 2561-2567
15. Vlasveld LT, Hekman A, Vyth-Dreese FA, Rankin EM, Scharenberg JGM, Voordouw AC, Sein JJ, Dellemijn TAM, Rodenhuis S and Melief CJM (1993) A phase I study of prolonged continuous infusion of low dose recombinant interleukin-2 in melanoma and renal cell cancer. Part II: immunological aspects. Br J Cancer 68: 559-567
16. Vuoristo M, Jantunen I, Pyrhonen S, Muhonen T and Kellokumpu-Lehtinen P (1994) A combination of subcutaneous recombinant interleukin-2 and recombinant interferon-α in the treatment of advanced renal cell carcinoma or melanoma. Eur J Cancer 30A: 530-532
17. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB and Oldham RK (1987) Constant infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898-905
18. Wiebke KA, Rosenberg SA and Lotze MT (1988) Acute immunologic effects of interleukin-2 therapy in cancer patients: decreased delayed type hypersensitivity response and decreased proliferate response to soluble antigens. J Clin Oncol 6: 1440-1449